Connect Biopharma Holdings Limited
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $-55.5M | $-15.6M | $-62.1M | $-118.1M | $-202.3M |
| Depreciation & Amortization | $704.0K | $660.0K | $720.0K | — | — |
| Depreciation | — | — | $707.0K | $723.0K | $486.0K |
| Amortization | — | — | — | — | — |
| Stock-Based Compensation | $3.7M | $6.7M | $5.4M | $6.9M | $9.0M |
| Net Cash from Operating Activities | $-51.2M | $-23.6M | $-47.7M | $-101.5M | $-84.3M |
| Investing Activities | |||||
| Capital Expenditures | $434.0K | $750.0K | $81.0K | $4.4M | $3.8M |
| Business Acquisitions | — | — | — | — | — |
| Net Cash from Investing Activities | $9.8M | $-3.5M | $75.0M | $-86.2M | $-5.2M |
| Financing Activities | |||||
| Dividends Paid | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — |
| Net Cash from Financing Activities | $1.1M | $227.0K | $45.0K | $-85.0K | $202.2M |
| Net Change in Cash | $-39.9M | $-27.4M | $26.7M | — | — |
| Free Cash Flow | $-51.6M | $-24.4M | $-47.8M | $-105.9M | $-88.2M |